Drugs /

ucpvax

Back to Drugs List

Overview

NCI Definition [1]:
A therapeutic peptide vaccine containing the human telomerase reverse transcriptase catalytic subunit (hTERT)-derived universal cancer peptides 2 (UCP2) and 4 (UCP4), and combined with the immunoadjuvant Montanide ISA 51 VG, with potential immunostimulating and antineoplastic activities. Vaccination with the CD4-specific telomerase peptide vaccine UCPVax activates the immune system to mount a T-helper 1 (TH1) CD4-positive T-lymphocyte immune response against and ultimately killing telomerase-expressing cells. Telomerase, a reverse transcriptase normally repressed in healthy cells, is overexpressed in most cancer cells and plays a key role in cellular proliferation.

Clinical Trials

View Clinical Trials for ucpvax

Ucpvax has been investigated in 3 clinical trials, of which 3 are open and 0 are closed. Of the trials investigating ucpvax, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open).

CDKN2A Overexpression, HPV Positive, and MGMT Promoter Methylation Negative are the most frequent biomarker inclusion criteria for ucpvax clinical trials.

Anal squamous cell carcinoma, cervical squamous cell carcinoma, and glioblastoma are the most common diseases being investigated in ucpvax clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Ucpvax
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating ucpvax and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
cd4-specific telomerase peptide vaccine ucpvax, ucp2/ucp4 cd4-specific telomerase peptide vaccine ucpvax
Drug Target(s) [2]:
MS4A1
NCIT ID [1]:
C129596

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.